Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus EXDENSUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus EXDENSUR.
ACTONEL vs EXDENSUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
EXDENSUR (generic name not specified) is a novel oral anticoagulant that selectively inhibits activated factor XI (FXIa), thereby reducing thrombin generation and preventing clot formation without significantly affecting hemostasis.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
5 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal elimination half-life is 8 hours in healthy adults, prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Primarily renal excretion of unchanged drug (85%) and minor biliary excretion (15%). Total clearance is 120 mL/min.
Category C
Category C
Bisphosphonate
Bisphosphonate